Detalhe da pesquisa
1.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Gynecol Oncol
; 184: 24-30, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277918
2.
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Gynecol Oncol
; 169: 27-33, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493574
3.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965291
4.
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.
Int J Gynecol Cancer
; 33(6): 922-928, 2023 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759000
5.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869143
6.
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Gynecol Oncol
; 167(3): 436-443, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36220670
7.
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Int J Gynecol Cancer
; 32(6): 799-803, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35318277
8.
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Int J Gynecol Cancer
; 31(10): 1369-1373, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34607820
9.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Int J Gynecol Cancer
; 31(7): 1031-1036, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33990353
10.
Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
J Cell Physiol
; 235(6): 5050-5058, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31912897
11.
Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review.
Oncology
; 98(4): 195-201, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32036368
12.
Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat
; 178(3): 485-492, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31451975
13.
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Gynecol Oncol
; 154(1): 138-143, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31079832
14.
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group.
Int J Gynecol Cancer
; 2022 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314461
15.
Massive haemoperitoneum caused by uterine leiomyoma: a case report.
J Obstet Gynaecol
; 40(5): 735-736, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31401927
16.
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
Cancer Treat Rev
; 125: 102701, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38422895
17.
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.
Crit Rev Oncol Hematol
; 199: 104379, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38718940
18.
Dostarlimab: From preclinical investigation to drug approval and future directions.
Hum Vaccin Immunother
; 19(1): 2178220, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762991
19.
Recent progress in the use of pharmacotherapy for endometrial cancer.
Expert Opin Pharmacother
; 24(1): 83-94, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35912837
20.
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data.
Cancer Manag Res
; 15: 1063-1072, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37790898